查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012892

生物可吸收聚合物市场：依产品、形态、製造流程、材料类型、应用和最终用户划分－2026-2032年全球市场预测

Bioresorbable Polymers Market by Product, Form, Manufacturing Process, Material Type, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，生物可吸收聚合物市场价值将达到 10.9 亿美元，到 2026 年将成长至 11.9 亿美元，复合年增长率为 11.90%，到 2032 年将达到 22.6 亿美元。

主要市场统计数据
基准年 2025 10.9亿美元
预计年份：2026年 11.9亿美元
预测年份 2032 22.6亿美元
复合年增长率 (%) 11.00%

生物可吸收聚合物是一种能够在生物环境中安全降解，并在指定寿命内保持其功能性能的材料。近年来，聚合物化学和加工技术的进步使得人们能够精确控制降解速率，提高生物相容性，并建构兼具治疗和结构功能的多功能结构。因此，这些材料正在成为医疗设备、药物传输和组织工程等领域的重要基础技术，而这些领域先前一直以永久性植入和不可降解系统为主导。

同时，转化科学与先进製造技术的融合正在催生纤维、薄膜、微粒和奈米结构，为临床医生和产品开发人员拓展了设计可能性。越来越多的临床前和临床证据为这些进展提供了支持，这些证据阐明了安全性特征和性能标准。因此，相关人员如今正处于一个关键的十字路口。生物可吸收解决方案的技术可行性已趋于成熟，而主要挑战正转向如何将其与法规结构、稳健的供应链以及临床认可相整合。

本导言为全面探讨材料类型、加工方法、特定应用需求以及加速推广应用并降低营运风险的策略措施奠定了基础。后续章节将为参与生物可吸收聚合物生态系的组织提供综合说明，内容涵盖技术演进、政策影响、市场细分洞察、区域差异、竞争资讯和实用建议。

聚合物化学、精密製造和临床需求的进展如何汇聚，重新定义生物可吸收医用材料的未来发展方向。

生物可吸收聚合物领域正经历一场变革，其驱动力来自材料创新、精密製造和跨领域合作。在材料层面，可用的化学成分范围已从传统的聚乳酸体系扩展到包括共聚物和特殊骨架结构。这些材料具有针对特定应用的降解性能和功能基团适用性。这种扩展的材料工具包使开发人员能够针对特定的临床情况（例如承重整形外科应用和精细的血管内治疗）优化材料的机械性能和降解特性。

评估 2025 年美国关税变化对企业营运和供应链调整的影响及其策略意义。

政策和贸易环境正对生物可吸收聚合物价值链产生实际影响，美国近期实施的将于2025年生效的关税措施改变了中间原料、特种聚合物和精密设备的进口趋势。这些政策调整迫使製造商重新评估其筹资策略，短期影响主要集中在依赖国际原材料供应的供应商以及依赖进口挤出、射出成型和微加工设备的资本财的供应商。

从详细的细分观点展示产品形式、製造流程、材料化学特性和应用需求如何影响策略优先顺序。

透过对产品、形态、製造流程、材料类型、应用和最终用户等各个维度进行分析，细分市场分析能够揭示潜在的机会和性能驱动因素。从产品角度来看，该领域涵盖纤维、薄膜、微粒和奈米材料，每种材料都有独特的功能优势。纤维提供定向强度和孔隙率控制；薄膜提供阻隔功能和可塑性；微粒可用作注射或植入式药物储存载体；奈米材料则支持细胞层面的靶向相互作用。同时，形态（液体、粉末或固体）决定了处理方法、灭菌方案和合适的下游製造技术，从而影响该解决方案可整合到哪些临床工作流程中。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势正在影响监管路径、製造地决策和临床试验。

地理因素在美洲、欧洲、中东和非洲以及亚太地区的技术采纳、监管趋势和供应链发展中发挥重要作用。在美洲，临床界和医保体系支持能够降低再次手术和长期照护成本的创新，这推动了人们对可吸收植入和局部给药解决方案的兴趣。法规环境强调安全性和临床证据，促进了强有力的临床试验和机构间伙伴关係，以加速实用化。

竞争格局洞察，重点介绍成熟企业、利基创新者和学术衍生公司如何塑造其商业化和合作策略。

生物可吸收聚合物领域的竞争格局呈现出多元化的特点，既有特种聚合物供应商，也有整合材料专业知识的医疗设备製造商，还有专注于新型化学品和设计结构的主导新兴参与企业。成熟企业凭藉其规模优势、成熟的生产平台和丰富的监管经验，致力于开发符合高合规性要求的应用，例如心血管和整形外科植入。这些成熟企业通常强调品管系统、可追溯性和广泛的临床数据，以提升市场接受度。

经营团队的策略重点是将聚合物科学的进步转化为扩充性的、经临床检验的、商业性可行性的解决方案。

产业领导者应优先考虑一系列切实可行的倡议，将科学潜力与实际应用结合，加速价值实现。首先，应投资进行可靠的材料表征和体外-体内相关性研究，将降解曲线与性能终点连结起来。这些数据将降低监管方面的不确定性，并增强临床医生的信心。其次，应推行模组化生产策略，在维持材料和製程控制的前提下，实现从试验规模到商业化生产规模的扩展。采用品质源自于设计 (QbD) 原则可以降低变异性，并加快医疗设备认证流程。

结合专家访谈、文献整合和比较技术评估的综合调查方法，确保了基于证据的实用见解。

本研究采用综合分析方法，结合对材料科学家、医疗设备开发人员、临床研究人员和供应链专家的访谈，以及对同行评审文献和监管文件的系统性回顾。原始数据经过结构化处理，旨在捕捉技术成熟度、製造限制、临床偏好和采购考虑。访谈主题在不同资讯来源间进行了交叉检验，以确认研究结果的有效性并识别通用趋势。

摘要强调了综合实施在将生物可吸收聚合物的创新转化为持续的临床影响方面所发挥的关键作用。

生物可吸收聚合物在材料科学、临床需求和生产能力三大领域的交会点占据战略地位。化学、加工技术和协作转化生态系统的进步降低了技术壁垒，并扩大了其在临床上的实际应用范围。然而，为了充分发挥这些材料的潜力，并确保其即使在大规模应用中也能保持稳定的性能，需要在证据收集、供应链设计和与监管机构合作等方面采取周密的计划。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生物可吸收聚合物市场：依产品分类

  • 纤维
  • 电影
  • 细颗粒物
  • 奈米材料

第九章：生物可吸收聚合物市场：依形式划分

  • 液体
  • 粉末
  • 固体的

第十章：生物可吸收聚合物市场：依製造製程划分

  • 吹塑成型
  • 挤压
  • 射出成型

第十一章：生物可吸收聚合物市场：依材料类型划分

  • 聚烷氢化物
  • 聚己内酯（PCL）
  • 聚乙醇酸（PGA）
  • 聚羟基烷酯（PHA）
  • 聚乳酸（PLA）

第十二章：生物可吸收聚合物市场：依应用领域划分

  • 药物输送系统
    • 缓释製剂
    • 标靶特异性递送系统
  • 医疗植入
    • 心血管支架
    • 整形外科植入
  • 组织工程
    • 鹰架设计
    • 干细胞支架
  • 创伤治疗装置
    • 黏合剂解决方案
    • 包扎材料

第十三章：生物可吸收聚合物市场：依最终用户划分

  • 生技公司
  • 医院和诊所
  • 製药公司
  • 研究机构

第十四章：生物可吸收聚合物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：生物可吸收聚合物市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章：生物可吸收聚合物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国生物可吸收聚合物市场

第十八章：中国生物可吸收聚合物市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Advanced Polymer Materials Inc.
  • Ashland Inc.
  • Corbion NV
  • DSM Biomedical
  • DURECT Corporation
  • Evonik Industries AG
  • Foster Corporation
  • Groupe PCAS
  • KLS Martin Group
  • Merck KGaA
  • Mitsubishi Chemical Group Corporation
  • NatureWorks LLC
  • Novamont SpA
  • Poly-Med Incorporated
  • REVA Medical, LLC
  • SEQENS SAS
  • Teijin Limited
  • Zeus Industrial Products, Inc.
Product Code: MRR-437D45957EE1

The Bioresorbable Polymers Market was valued at USD 1.09 billion in 2025 and is projected to grow to USD 1.19 billion in 2026, with a CAGR of 11.00%, reaching USD 2.26 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.09 billion
Estimated Year [2026] USD 1.19 billion
Forecast Year [2032] USD 2.26 billion
CAGR (%) 11.00%

Bioresorbable polymers represent a class of materials engineered to degrade safely within biological environments while delivering functional performance during their intended service life. Recent advances in polymer chemistry and processing techniques have enabled precisely tuned degradation kinetics, enhanced biocompatibility, and multifunctional constructs that serve therapeutic and structural roles. As a result, these materials are emerging as critical enablers across medical devices, drug delivery, and tissue engineering, where permanent implants or nondegradable systems previously dominated.

Concurrently, translational science is converging with advanced manufacturing to produce architectures at the fiber, film, micro-particle, and nanoscale levels, expanding the design space for clinicians and product developers. These developments are supported by a growing corpus of preclinical and clinical evidence that clarifies safety profiles and performance benchmarks. Therefore, stakeholders now face a pivotal moment: the technical plausibility of bioresorbable solutions has matured, and the primary challenges shift toward integration with regulatory frameworks, supply chain robustness, and clinical acceptance.

This introduction sets the stage for a nuanced exploration of material classes, processing modalities, application-specific demands, and strategic actions that can accelerate adoption while mitigating operational risk. The succeeding sections synthesize technological shifts, policy impacts, segmentation intelligence, geographic variations, competitive positioning, and pragmatic recommendations for organizations engaged in the bioresorbable polymer ecosystem.

How advances in polymer chemistry, precision manufacturing, and clinical demand are converging to redefine the future pathways for resorbable medical materials

The landscape for bioresorbable polymers is undergoing transformative shifts driven by material innovation, precision manufacturing, and cross-disciplinary collaboration. At the material level, the palette of available chemistries has broadened beyond traditional polylactide systems to include copolymers and specialty backbones that afford tailored degradation and functional group compatibility. This expanded material toolkit enables developers to optimize mechanical properties and degradation profiles for specific clinical contexts, such as load-bearing orthopedic applications or delicate vascular interventions.

In manufacturing, additive and advanced molding techniques are moving from prototyping to regulated production, enabling architected scaffolds and device features previously unattainable with conventional methods. Such process innovation interacts with material science to reduce variability and enhance reproducibility, which in turn eases regulatory review pathways. Additionally, there is a growing emphasis on scalable sterilization approaches and quality-by-design paradigms that align with industry expectations for consistency.

Healthcare delivery trends are also reshaping demand: clinicians increasingly prioritize devices that reduce secondary procedures and long-term foreign body complications, which supports interest in resorbable alternatives for stents, fixation devices, and localized drug depots. Moreover, cross-sector collaborations-linking academic groups, clinical investigators, and industry developers-accelerate translational pathways by combining domain expertise, shared biobanking resources, and translational trial networks. Collectively, these shifts point toward an ecosystem that is more modular, evidence-driven, and capable of bringing complex bioresorbable solutions to market with improved predictability.

Assessment of the operational and supply chain adjustments prompted by United States tariff changes in 2025 and their strategic implications

Policy and trade environments have a tangible influence on the bioresorbable polymers value chain, and recent tariff measures introduced in the United States in 2025 altered import dynamics for intermediate feedstocks, specialty polymers, and precision equipment. These policy adjustments have prompted manufacturers to reassess sourcing strategies, with near-term effects concentrated on suppliers dependent on international raw-material flows or on capital goods imported for extrusion, injection molding, and microfabrication equipment.

In response, some manufacturers have diversified supply bases or engaged in contract manufacturing closer to end markets to mitigate border-related headwinds. Others have accelerated qualification of alternative polymer grades and localized suppliers to reduce exposure to tariff-induced cost volatility. The cumulative operational effect includes tighter inventory management, renegotiated supplier contracts, and increased investment in logistic resiliency. While larger multinational producers have absorbed a portion of the impact through integrated supply networks, smaller and mid-sized producers felt acute pricing and lead-time pressures that influenced project timelines and partnership negotiations.

Importantly, these tariff-driven adjustments also stimulated conversations around vertical integration for critical intermediates and enhanced domestic capacity planning. Regulatory alignment and procurement policies that favor locally supplied materials can further shape adoption pathways. For decision-makers, the key takeaway lies in evaluating supplier risk, maintaining flexible sourcing strategies, and anticipating procurement timelines that account for potential trade-policy volatility.

Deep segmentation perspective showing how product forms, manufacturing routes, material chemistries, and application demands inform strategic prioritization

Segmentation analysis reveals nuanced opportunities and performance drivers when examined across product, form, manufacturing process, material type, application, and end-user dimensions. When evaluated on the product axis, the field encompasses fibers, films, micro-particles, and nanomaterials, each offering distinct functional advantages: fibers provide directional strength and porosity control, films enable barrier and conformability functions, micro-particles facilitate injectable or implantable drug depots, and nanomaterials support targeted interactions at the cellular level. In parallel, the form factor-liquid, powder, or solid-dictates handling, sterilization choices, and suitable downstream fabrication approaches, influencing which clinical workflows a solution can enter.

Manufacturing processes span blow molding, extrusion, and injection molding, and each presents trade-offs among throughput, geometric complexity, and material compatibility. Designers select processes to match device geometry, scale, and precision needs, recognizing that process-induced stresses and thermal histories can materially affect degradation behavior. Material type remains a primary determinant of performance, with chemistries such as polyanhydrides, polycaprolactone, polyglycolic acid, polyhydroxyalkanoate, and polylactic acid offering diverse degradation kinetics and mechanical profiles that align with specific clinical demands.

Application-driven segmentation illustrates where value accrues: drug delivery systems, including controlled-release formulations and target-specific vehicles, exploit resorbable matrices to localize therapy and minimize systemic exposure. Medical implants, notably cardiovascular stents and orthopedic implants, leverage temporary mechanical support followed by safe resorption to eliminate long-term foreign body presence. Tissue engineering efforts focus on scaffold designs and stem cell scaffolding to guide regeneration, while wound healing devices such as adhesive solutions and bandaging materials use transient material presence to promote repair. Finally, end-user categories-biotechnology companies, hospitals and clinics, pharmaceutical companies, and research institutes-shape adoption through differing procurement cycles, regulatory expectations, and clinical deployment pathways. Together, these segmentation lenses inform prioritization of R&D investment, manufacturing capacity, and commercialization strategies.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping regulatory pathways, manufacturing footprint decisions, and clinical adoption

Geographic considerations play a significant role in technology adoption, regulatory trajectories, and supply chain architecture across the Americas, Europe Middle East & Africa, and Asia-Pacific regions. In the Americas, clinical communities and reimbursement structures favor innovations that reduce repeat interventions and long-term care costs, which supports interest in resorbable implants and localized drug delivery solutions. The regulatory environment emphasizes safety and clinical evidence, prompting robust clinical trial engagement and institutional partnerships that can accelerate translation.

Across Europe, the Middle East & Africa, regulatory harmonization initiatives and centralized review processes in some jurisdictions facilitate pathway clarity but also require comprehensive technical documentation and post-market surveillance commitments. Clinical preference patterns and procurement mechanisms vary, leading companies to adopt regionally tailored market-entry strategies. Similarly, EMEA procurement often stresses lifecycle cost and clinical outcomes, reinforcing the value proposition of devices that demonstrably reduce long-term complications.

The Asia-Pacific region exhibits a heterogeneous but rapidly maturing ecosystem, with significant manufacturing capacity and growing clinical trial activity. Several economies in the region are investing in domestic polymer and medical-device capabilities, which creates both competitive advantages and collaborative opportunities for global players. Supply chain proximity in Asia-Pacific can reduce lead times for regional manufacturers, while regulatory modernization in many markets is creating clearer clinical pathways for novel resorbable solutions. Taken together, these regional dynamics inform decisions about manufacturing footprints, clinical partnerships, and regulatory engagements to optimize adoption and patient outcomes.

Competitive landscape insights highlighting how incumbents, niche innovators, and academic spinouts are shaping commercialization and partnership strategies

Competitive dynamics within the bioresorbable polymer landscape are characterized by a mix of specialty polymer suppliers, device manufacturers with integrated materials expertise, and research-driven entrants focused on novel chemistries or architected structures. Established firms leverage scale, validated manufacturing platforms, and regulatory experience to pursue high-compliance applications such as cardiovascular and orthopedic implants. These incumbents often emphasize quality management systems, traceability, and extensive clinical datasets to support market acceptance.

At the same time, smaller and niche players contribute innovation in formulation science, advanced processing, and application-specific adaptations. Their agility enables rapid iteration on material blends and surface modifications that can address unmet clinical needs. Collaboration between specialized material developers and device manufacturers is increasingly common, yielding co-development agreements, licensing arrangements, and strategic partnerships that align material properties with device function.

Furthermore, academic spin-outs and research institutes remain important sources of disruptive concepts, particularly in areas like stimulus-responsive degradation, hierarchical scaffold architectures, and integration of biologics. For organizations navigating this competitive landscape, differentiation often hinges on demonstrable clinical benefit, manufacturability at scale, and a clear regulatory strategy. Strategic alliances, targeted IP protection, and investments in manufacturing qualification are prudent mechanisms to convert technical advantage into commercial traction.

Actionable strategic priorities for executives to convert polymer science advancements into scalable, clinically validated, and commercially viable solutions

Industry leaders should prioritize a set of pragmatic actions that bridge scientific promise with operational execution to accelerate value realization. First, invest in robust materials characterization and in vitro-to-in vivo correlation studies that link degradation profiles to performance endpoints. Such data will reduce regulatory uncertainty and support clinician confidence. Second, pursue modular manufacturing strategies that allow scaling from pilot to commercial volumes while preserving material and process control; adopting quality-by-design principles can reduce variability and speed device qualification.

Third, develop supply chain resilience through diversified sourcing, strategic supplier partnerships, and where appropriate, localized production for critical intermediates to mitigate trade-policy or logistic disruptions. Fourth, structure clinical evidence generation to demonstrate meaningful patient outcomes and economic value; partnering with healthcare systems and forming registry networks can produce longitudinal data that reinforce reimbursement positions. Fifth, cultivate cross-functional teams that integrate regulatory, clinical, manufacturing, and commercial expertise early in development to avoid late-stage rework and to align product features with adoption drivers.

Finally, consider IP strategies and collaborative models that unlock complementary capabilities, whether through licensing, joint ventures, or co-development agreements. By executing these recommendations in parallel, organizations can reduce time-to-clinic, lower deployment risk, and strengthen the commercial case for advanced bioresorbable solutions.

Comprehensive methodology combining expert interviews, literature synthesis, and comparative technical evaluation to ensure evidence-based, actionable insights

This research synthesis integrates primary interviews with materials scientists, device developers, clinical investigators, and supply chain specialists, complemented by a systematic review of peer-reviewed literature and regulatory documentation. Primary inputs were structured to capture technology readiness, manufacturing constraints, clinical preferences, and procurement considerations. Interview themes were triangulated across sources to validate findings and identify convergent trends.

Analytical methods included comparative evaluation of material classes against application-specific performance criteria, process compatibility assessments for common manufacturing routes, and scenario analysis of supply chain disruptions. Emphasis was placed on cross-validation: technical claims from developers were checked against independent bench reports and clinical trial registries where available. Regulatory considerations were derived from public agency guidance, product clearances, and post-market surveillance summaries to ensure alignment with current expectations.

The research approach also prioritized transparency in assumptions and data provenance. Wherever practical, limitations and knowledge gaps are identified to guide future investigation and to support evidence-based decision-making by stakeholders considering investments, partnerships, or clinical programs in the bioresorbable polymers domain.

Concluding synthesis emphasizing the pivotal role of integrated execution in translating bioresorbable polymer innovations into durable clinical impact

Bioresorbable polymers occupy a strategic intersection of materials science, clinical need, and manufacturing capability. Advances in chemistries, processing technologies, and collaborative translational ecosystems have reduced technical barriers and expanded the portfolio of viable clinical applications. However, realizing the full potential of these materials requires deliberate action across evidence generation, supply chain design, and regulatory engagement to ensure consistent performance at scale.

Stakeholders that integrate rigorous materials characterization, scalable manufacturing practices, and targeted clinical evidence programs will be best positioned to capture clinical and economic value. Policy dynamics and regional differences in regulatory and procurement practices further emphasize the need for localized strategies and flexible supply networks. Ultimately, organizations that align scientific innovation with operational discipline and strategic partnerships will create the most durable pathways to adoption, delivering patient-centric solutions that reduce intervention burden and improve long-term outcomes.

This conclusion underscores a pragmatic view: technical readiness has advanced substantially, but strategic execution remains the differentiator between prototype promise and widespread clinical impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bioresorbable Polymers Market, by Product

  • 8.1. Fibers
  • 8.2. Films
  • 8.3. Micro-Particles
  • 8.4. Nanomaterials

9. Bioresorbable Polymers Market, by Form

  • 9.1. Liquid
  • 9.2. Powder
  • 9.3. Solid

10. Bioresorbable Polymers Market, by Manufacturing Process

  • 10.1. Blow Molding
  • 10.2. Extrusion
  • 10.3. Injection Molding

11. Bioresorbable Polymers Market, by Material Type

  • 11.1. Polyanhydrides
  • 11.2. Polycaprolactone (PCL)
  • 11.3. Polyglycolic Acid (PGA)
  • 11.4. Polyhydroxyalkanoate (PHA)
  • 11.5. Polylactic Acid (PLA)

12. Bioresorbable Polymers Market, by Application

  • 12.1. Drug Delivery Systems
    • 12.1.1. Controlled Release Formulations
    • 12.1.2. Target-Specific Vehicles
  • 12.2. Medical Implants
    • 12.2.1. Cardiovascular Stents
    • 12.2.2. Orthopedic Implants
  • 12.3. Tissue Engineering
    • 12.3.1. Scaffold Designs
    • 12.3.2. Stem Cell Scaffolding
  • 12.4. Wound Healing Devices
    • 12.4.1. Adhesive Solutions
    • 12.4.2. Bandaging Materials

13. Bioresorbable Polymers Market, by End-User

  • 13.1. Biotechnology Companies
  • 13.2. Hospitals and Clinics
  • 13.3. Pharmaceutical Companies
  • 13.4. Research Institutes

14. Bioresorbable Polymers Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Bioresorbable Polymers Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Bioresorbable Polymers Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Bioresorbable Polymers Market

18. China Bioresorbable Polymers Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Advanced Polymer Materials Inc.
  • 19.6. Ashland Inc.
  • 19.7. Corbion NV
  • 19.8. DSM Biomedical
  • 19.9. DURECT Corporation
  • 19.10. Evonik Industries AG
  • 19.11. Foster Corporation
  • 19.12. Groupe PCAS
  • 19.13. KLS Martin Group
  • 19.14. Merck KGaA
  • 19.15. Mitsubishi Chemical Group Corporation
  • 19.16. NatureWorks LLC
  • 19.17. Novamont S.p.A.
  • 19.18. Poly-Med Incorporated
  • 19.19. REVA Medical, LLC
  • 19.20. SEQENS SAS
  • 19.21. Teijin Limited
  • 19.22. Zeus Industrial Products, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIORESORBABLE POLYMERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIORESORBABLE POLYMERS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BIORESORBABLE POLYMERS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FIBERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FIBERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FIBERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FILMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FILMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FILMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MICRO-PARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MICRO-PARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MICRO-PARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY NANOMATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY NANOMATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY NANOMATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY SOLID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY SOLID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY SOLID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BLOW MOLDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BLOW MOLDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BLOW MOLDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY EXTRUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY EXTRUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY EXTRUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY INJECTION MOLDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY INJECTION MOLDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY INJECTION MOLDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYANHYDRIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYANHYDRIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYANHYDRIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYCAPROLACTONE (PCL), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYCAPROLACTONE (PCL), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYCAPROLACTONE (PCL), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYGLYCOLIC ACID (PGA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYGLYCOLIC ACID (PGA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYGLYCOLIC ACID (PGA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYHYDROXYALKANOATE (PHA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYHYDROXYALKANOATE (PHA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYHYDROXYALKANOATE (PHA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYLACTIC ACID (PLA), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYLACTIC ACID (PLA), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY POLYLACTIC ACID (PLA), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY CONTROLLED RELEASE FORMULATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY CONTROLLED RELEASE FORMULATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY CONTROLLED RELEASE FORMULATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY TARGET-SPECIFIC VEHICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY TARGET-SPECIFIC VEHICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY TARGET-SPECIFIC VEHICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY CARDIOVASCULAR STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY CARDIOVASCULAR STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY CARDIOVASCULAR STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY SCAFFOLD DESIGNS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY SCAFFOLD DESIGNS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY SCAFFOLD DESIGNS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY STEM CELL SCAFFOLDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY STEM CELL SCAFFOLDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY STEM CELL SCAFFOLDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY ADHESIVE SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY ADHESIVE SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY ADHESIVE SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BANDAGING MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BANDAGING MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BANDAGING MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 206. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 208. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 209. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 213. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 214. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 215. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 216. GCC BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 239. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 241. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 242. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 248. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 249. G7 BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 250. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 251. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 252. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 253. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 254. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 256. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 259. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 260. NATO BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL BIORESORBABLE POLYMERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA BIORESORBABLE POLYMERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY DRUG DELIVERY SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY MEDICAL IMPLANTS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY TISSUE ENGINEERING, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY WOUND HEALING DEVICES, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA BIORESORBABLE POLYMERS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)